Recursion Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|
Revenue | $4,511 | $26,082 | $14,417 | $13,794 |
Gross Profit | -8,283 | 14,003 | 1,318 | -772 |
EBITDA | -165,343 | -87,924 | -89,669 | -84,732 |
EBIT | -178,294 | -95,122 | -97,669 | -92,132 |
Net Income | -178,906 | -95,675 | -97,540 | -91,373 |
Net Change In Cash | 4,511 | 26,082 | 14,417 | 13,794 |
Free Cash Flow | -117,078 | -60,787 | -86,401 | -108,953 |
Cash | 594,350 | 427,647 | 476,124 | 299,521 |
Basic Shares | 336,035 | 282,583 | 242,196 | 236,019 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $58,839 | $44,575 | $39,681 | $10,000 |
Gross Profit | 13,601 | 1,988 | -8,594 | 10,000 |
EBITDA | -426,722 | -299,566 | -233,971 | -174,370 |
EBIT | -463,216 | -323,968 | -245,727 | -182,775 |
Net Income | -463,661 | -328,066 | -239,421 | -178,074 |
Net Change In Cash | 58,839 | 44,575 | 39,681 | 10,000 |
Cost of Revenue | 28,182 | |||
Free Cash Flow | -372,869 | -300,332 | -120,883 | -198,412 |
Cash | 594,350 | 391,565 | 549,912 | 285,116 |
Basic Shares | 274,207 | 207,853 | 175,537 | 170,272 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-12-31 | -$0.53 |
2024-09-30 | -$0.34 |
2024-06-30 | -$0.40 |
2024-03-31 | -$0.39 |
